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1. Introduction 
Gliomas are the most common form of brain tumors, contributing to more than half of the 
incidence of brain tumors. They are derived from three basic types of glial cells: astrocytes, 
oligodendrocytes and ependymal cells. The most frequent are diffusely infiltrating 
astrocytomas, further classified into astroytomas (A), anaplastic astrocytomas (AA) and 
glioblastoma, equivalent to World Health Organization (WHO) grade II, II and IV, 
respectively (Kleihues & Cavenee, 2000). The term glioblastoma is used synonymously with 
glioblastoma multiforme (GBM), which suggests, the histopathology of this tumor is 
extremely variable (Kleihues & Cavenee, 2000). GBM is the most common and lethal type of 
astrocyte-derived tumor, corresponding to 50% of adult primary brain tumor cases, 
followed by anaplastic astrocytoma (30%) and astrocytoma (20%) (Greenberg, 2010). GBM 
may develop from astrocytoma or anaplastic astrocytoma (secondary GBM), but more 
frequently they manifest after a short clinical history de novo, without any evidence of a less 
malignant precursor lesion (primary GBM) (Farhadi & Rutka, 2008). Although primary 
brain tumors are relatively rare compared with carcinomas, they are characterized by higher 
mortality rates and increased disability. The overall annual incidence rate of primary 
malignant and benign brain tumors in developed countries is approximately 15 per 100,000 
individuals, and for primary malignant brain tumors it is 7 per 100,000 (Minn et al., 2008). 
Brain tumor incidence and mortality have increased by up to 300% over the past 3 decades 
primarily in people aged over 75 years (Davis et al., 1996 as cited in Minn et al., 2008; 
Wrensch et al, 1993 as cited in Minn et al., 2008). 
Malignant gliomas are among the most challenging of all cancers to treat successfully. The 
tumor cells vigorously invade surrounding tissue, which renders complete surgical 
resection difficult and contributes to the high incidence of the recurrence (Merzak et al., 
1995). Invasion of glioma cells into adjacent brain tissue is dependent on their interaction 
with the extracellular matrix (ECM) and possible destruction of matrix barriers (Pilkington, 
1994). Tumor cells at the invasive front have to detach from the primary tumor mass and re-
attach to ECM components or to surrounding tissue elements. In general, invasiveness may 
result in deformation and destruction of the brain architecture which leads to the fatal 
outcome for the patient. Proteolytic modification of ECM components, such as laminin and 
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fibronection, is believed to facilitate the invasive spread of tumor cells (Gladson, 1999; 
Goldbrunner et al., 1999). Lysosomal cysteine cathepsins have been implicated in tumor 
progression. Proteolytic enzymes, including cahtepsins (Cats), mediate the invasion process, 
either acting alone or participating in proteolytic cascades (Schmitt et al., 1992; Sloane et al., 
1994). Increased activity of proteolytic enzymes is observed during brain tumor progression 
(Frosch & Sloane, 1998; Levičar et al., 2003). Cathepsins are responsible for intracellular 
protein turnover and are vitally important for normal cell and organ development. The 
activity of the cysteine cathepsins can be regulated at various levels, ultimately by their 
endogenous inhibitors (Lah & Kos, 1998; Calkins & Sloane, 1995). In brain tumors, down-
regulation of the total inhibitory activity of cystatins has been observed, presumably 
contributing to tumor malignancy (Sivaparvathi et al., 1996a).  
In addition, tumor growth is critically dependent on blood supply and the development of 
new capillaries. In the case of tumor cell-induced angiogenesis, endothelial cells invade 
surrounding tissue in a process similar to that observed for tumor cells (Paku, 1998).  
Human GBM also contains a various amounts of brain tumor stem-like precursor cells 
(BTSC) (Singh et al., 2003), which indicates a hierarchical model of tumorigenesis. The 
BTSCs display self-renewal potential, ex vivo multipotency and, most importantly, the 
ability to establish and expand the tumor in vivo. Moreover, genetic analyses of the BTSC in 
various patients have revealed distinct patterns of up-regulated genes, including patient-
specific genes expression (Galli et al., 2004).  
Despite recent advances in neuro-imaging, neurosurgical resection techniques and the 
development of novel adjuvant therapies, the long-term survival of patients suffering from 
malignant glioma remains low. Although treatment with temozolomide and radiotherapy 
improved median survival after diagnosis of GBM from 12 months to 14 months (Kalkanis 
& Rosenblum, 2008), the survival rate still ranges from a few months to several years, which, 
together with the poor prognosis, points the need for new, independent prognostic factors 
that may enable individualized treatment modalities, including molecular based therapies, 
of patients with unfavourable prognosis. Our studies are aimed to reveal differential 
expression and compare the prognostic significance of potential biological markers in 
glioma patients. 
2. Immunohistochemical investigation of human gliomas  
High-grade gliomas often demonstrate immunoreactivity for various markers. Such biologic 
markers could be used to assess the patient prognosis and may thus provide the new 
information regarding the time of glioma recurrence. In recent years we investigated the 
possible prognostic significance of different biological markers. The particularity of present 
report is the fusion of author’s clinical work with his own experimental studies on animal 
models. 
2.1 The animal models for experimental studies of human malignant brain tumors 
The objective of experimental neuro-oncology is to contribute to a better understanding of 
human malignant brain tumors (Wechsler et al., 1989). To this end, the development of 
several animal models has provided specific clues about the formation of gliomas 
(Pilkington et al., 1997). Such animal models are also beneficial for selective molecular and 
biochemical analyses of tumor markers (Brem & Sawaya, 2004).  
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Previously, either commercial cell lines derived from human GBM or multicellular tumor 
spheroids from human gliomas have been used as a model for the study of brain tumor 
invasion (Bjerkvig et al., 1990; Engebraaten et al., 1999). Since all these cell types can grow in 
vitro, the cultures must be characterized to ascertain the cell subpopulations which have 
been selected through the culture conditions. Morphological characterization is not 
sufficient and a panel of markers may be required to define the populations present. 
However, as the cells adapt to the tissue culture conditions, they may lose the ability to 
express one or more of these markers. The need for better and more relevant brain tumor 
models is generally acknowledged.  
2.1.1 U87 human glioblastoma cell xenografts in rat brains and on the chicken 
chorioallantoic membrane 
The objective of our experimental work was to develop a simple and cheap animal model, 
with high tumor take rate, for brain tumor progression studies (Strojnik et al., 2006; Strojnik 
et al., 2010). A tumorigenesis model was presented, originating from tumor spheroids 
prepared from U87 human glioblastoma cell line, in the brain of rats and on the chick 
chorioallantoic membrane (CAM). U87 cells are considered to be a rapidly proliferating cell 
line, which can be grown in culture as monolayers and tumor spheroids. The U87 cell 
suspension, or precultured U87 tumor spheroids, was inoculated into the brain of 4-week-
old rats and on CAM on embryonic day seven.  
 
 
Fig. 1. Coronal rat brain tissue sections demonstrated solid, well demarcated, grayish tumor 
with an area of hemorrhage (arrow). 
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The resulting first generation tumors that were induced in rats were also transferred 
through serial transplantations from rat to rat, to obtain second and third generation 
tumors. The macroscopic tumor appearance, histopathology and immunohistochemistry of 
selected relevant tumor progression markers were monitored in U87 human glioblastoma 
cells xenografted into the brain of rats. In accordance with other reports, maximum 
progressive tumor growth was observed after 2 - 3 weeks (Wechsler et al., 1989). According 
to the WHO classification of human brain tumors (Kleihues & Cavenee, 2000), the 
transplantation tumors demonstrated features of anaplastic astrocytic tumor (WHO grade 
III), but become increasingly similar to glioblastomas (WHO grade IV) in the second and 
third generations. Parallel to this progression, increasing neovascularization and tumor 
necrosis was observed, both characteristic of glioblastoma. The benefits of inoculation of 
pre-cultured small tumor spheroids have been well described (Bjerkvig et al., 1990; 
Engebraaten et al., 1999). However, it should be stressed that spheroids from a biopsy 
specimen consist of heterogeneous cell populations, e.g. vascular elements (endothelial cells, 
pericytes), other mesenchyme-derived cells (fibroblasts) and microglia (a type of 
differentiated tissue macrophage) (Bressler et al, 1985; Badie & Schartner, 2001), requiring 
more careful characterization of the cellular composition of the inoculated spheroids when 
interpreting the resulting tumor behavior. In contrast, U87 cell-inoculated tumors have a 
relatively isomorphos cellular composition, due to their clonal origin, and further tumor 
development can be followed during subsequent generations, with respect to 
dedifferentiation of the tumor cells and induced recruitment of stromal cells from the tumor 
microenvironment (Mueller & Fusenig, 2004). The panel of marker protein expressions were 
followed in the first, second and third generations of tumors.  
Anyway, the rodent models are somewhat limited by costs, experimental duration, variability 
and major ethical concerns, as well as by the difficulty of obtaining morphological data during 
tumor progression, resulting in large numbers of animals required to obtain conclusive results 
(Hagedorn et al., 2000). Another system consists of a human tumor grown in a xenogeneic 
host, the chick embryo. Consequently, we developed a tumorigenesis model, originating from 
the U87 human glioblastoma cell line, on the CAM, a densely vascularised extra-embryonic 
tissue (Strojnik et al., 2010). A few studies in chick embryos have been undertaken by others, 
but the primary focus was to demonstrate metastatic potential and not local invasiveness 
(Chambers et al., 1990; Ossowski & Reich, 1980). Our study aimed to compare the expression 
of various immunohistochemical markers of U87 cells and spheroids in culture and in rat brain 
with those grown on the CAM membrane. The macroscopic tumor appearance, 
histopathology and immunohistochemistry of selected relevant tumor progression markers 
were monitored in U87 human glioblastoma cells xenografted on the chick embryo CAM. In 
accordance with other reports, tumor growth was observed and well established tumors were 
seen after seven days in the CAM model.  
There were few differences in histological appearance between tumor models. In both tumor 
models, the full range of cytological features of human glioblastomas were observed, 
including astrocytes, small anaplastic cells, spindle cells and giant cells. In rats, tumors were 
more sharply demarcated from the surrounding brain, while on CAM, tumor nodules grew, 
with smaller groups of tumor cells growing apart from the gross tumor mass. These cells 
were usually within the connective tissue with some also attached to the vessel walls. This 
might be the result of how the tumor cells initially seeded upon inoculation; however, it 
may possibly mean that this model is more suitable for studying tumor invasiveness.  
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Fig. 2. Tumor nodules were seen on CAM one week after inoculation of U87 cells. Note 
small satellite tumors apart from the main tumor mass 
 
 
(a) 
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(b) 
Fig. 3. Within the CAMs, loosely connective tissue with blood vessels two tumor nodules 
can be seen (arrows) (H&E, x4) (a); all tumors in rats were sharply demarcated against the 
surrounding brain tissue (H&E, x40) (b) 
The immunohistochemical staining of animal samples was performed for Ki-67, p53, 
vimentin, glial fibrillary acidic protein (GFAP), S100, CD3, CD20, synaptophysin, 
cathepsin B, cathepsin L, CD68, vascular endothelial growth factor (VEGF), and leukocyte 
esterase. The staining of rat brain sections for nestin, musashi and kallikrein 6 was also 
done.   
Ki-67 antigen expression is a measure of the proportion of cellular and, hence, biological 
aggressiveness in malignancy (Scott et al., 1991; Wilson et al., 1996). The index of 
proliferation, Ki-67 LI, was high in all samples, but the fraction of Ki-67-positive cells was 
higher in U87 cell suspension and in rats compared to the spheroids and CAM tumors, 
indicating increased proliferation in the rat model of tumorigenicity. 
The p53 tumor suppressor gene is frequently mutated in glioblastomas (Newcomb et al., 
1993). Mutations within the p53 gene often results in aberrant expression of the p53 protein, 
leading to protein accumulation within the nucleus of the cells. The p53 protein is involved 
in regulation of the cell cycle and it has been speculated that the presence of abnormal 
amounts of p53 protein is associated with increased rates of proliferation (Cunningham et 
al., 1997). It was found that the percentage of p53-positive nuclei, which was higher in the 
tumors grown on the CAM than on rats, did not correlate with the Ki-67 LI. Other 
researchers have also reported little correlation between this pair of immunohistochemical 
markers (Cunningham et al., 1997; Balčiũnienė et al., 2009).  
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Fig. 4. In tumor grown on CAM many nuclei stained positively for p53 (x40) 
Vimentin is an intermediate filament protein, which marks the mesenchymal cell 
phenotype. In the course of development of the nervous system, vimentin appears first in 
immature glial cells (Dahl et al., 1981), but rapidly decreases as glial fibrillary acidic protein 
(GFAP) appears concomitantly with myelination (Dahl, 1981). In mature astroglia, vimentin 
and GFAP coexist, and normal, reactive and neoplastic astrocytes have been found to 
contain variable amounts of both (Yung et al., 1985). In our works (Strojnik et al., 2006; 
Strojnik et al., 2010) it was revealed that high production of vimentin by the tumor cells was 
preserved in the host in both animal models, thus showing that the U87 clone consists of 
immature cells. Due to strong and specific staining of the tumor cells, it facilitated 
visualization of satellite tumors and migrating tumor cells away from the main tumor mass.  
GFAP is mostly restricted to mature astrocytes (Lazarides, 1982). In human malignant 
gliomas, co-expression of GFAP and vimentin has been reported (Herpes, 1996). This was 
not the case in the animal models used in our study (Strojnik et al., 2010). Although the U87 
cell suspension presented a moderate immune reaction for GFAP, this was completely 
absent from the induced tumors. This does not necessarily mean that a cell is of non-glial 
origin, but the ability to synthesize GFAP after further dedifferentiation of the U87 cells in 
the host is gradually lost.  
The S100 family of calcium-binding proteins contains approximately 16 members, each of 
which exhibits a unique pattern of tissue/cell type-specific expression. Although the 
distribution of these proteins is not restricted to the nervous system, the implication of 
several members of this family in nervous system development, function, and disease has 
sparked new interest in these proteins. Different forms of malignant tumors exhibit dramatic 
changes in the expression of S100 proteins (Sedeghat & Notopoulos, 2008; Sen & Belli, 2007). 
Only moderate S100 immunoreactivity was detected in the U87 cell suspension and weak 
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expression in the spheroids. Tumors in both animal models were S100 negative, which can 
be explained by the possible down-regulation of S100 expression following tumor 
dedifferentiation (Bressler et al., 1985). 
 
 
Fig. 5. All of the CAM tumor cells presented a strong and specific immune reaction for 
vimentin. Vessel walls stained positively for vimentin also (x40) 
CD3 is a marker of T lymphocytes. Heterologous transplantation of human tumor cells into 
animals inevitably leads to immunological response of the host. Cytotoxic T lymphocytes 
have been implicated as the effectors cell mediating graft rejection (Bierer et al., 1985). Only 
small numbers of CD3-positive cells were seen in tumor grown on CAM, whereas in rats 
more CD3-positive cells were seen indicating that some sort of immune response is also 
present in this immunoincompetent hosts or that these CD3-positive cells might be “T-like” 
cells, but not actual T-cells, which adopted T lymphocytes phenotype during the 
dedifferentiation. As expected, no CD3-positive cells were observed in suspension, neither 
in spheroids nor outside the tumor in the host.  
CD20 is expressed on all stages of B cell development, except the first and the last stages. It 
is also found on skin melanoma cancer stem cells (Fang et al., 2005). No CD20-positive cells 
were detected in any of the models used in our study. This might be partially explained by 
the fact that neither B lymphocytes nor antibodies in the circulation nor in the graft itself are 
required for first-set graft rejection (Hall et al., 1978).  
Synaptophysin is a reliable marker for the identification of normal neuroendocrine cells and 
neuroendocrine neoplasm (McKeever, 1998). Only weak staining was observed in some of 
the tumor cells in suspension and in spheroids, but no staining was observed in animal 
tumor models, indicating that tumors induced by U87 clone underwent further 
dedifferentiation in the host. In humans, pure glial tumors do not usually express 
synaptophysin.  
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As expected, our study found strong Cat B staining in culture and in all of the animal 
models, where not only tumor cells but also endothelial cells stained positively for Cat B. 
Interestingly, stronger staining for Cat B in tumors was noted in rats than in chicken 
embryos. This could partially be explained by the relative ease of spreading of the tumor 
cells in the loose connective tissue of the CAM compared to the brain where more 
proteolytic activity is needed. We found Cat L staining in tumor cells in culture and in both 
animal models. Stronger staining for Cat L in tumors was noted in chicken than in rats. 
Staining with Cat L antibody revealed strong reaction in tumor cells, but there was no 
staining in the vascular endothelia. Stronger Cat L staining has been noted in the tumor 
centre, indicating slightly different roles of two cysteine proteases (Cat B and Cat L) in local 
invasiveness and in the malignant transformation of brain tumor cells.  
 
 
Fig. 6. Strong immunostaining for Cat B was noted in all samples, especially in rats. 
Vascular endothelia also stained positive for Cat B (40x) 
CD68 is a specific marker for macrophage and also resting microglia (Hulette et al., 1992). 
Considered as immune effector cells of the CNS, the microglia represent a major component 
of the inflammatory cells found in malignant gliomas (Badie et al., 1999). In accordance to 
others (Leenstra et al., 1995) our studies also found strong CD68 expression in U87 human 
glioblastoma cell suspension, in U87 spheroids, as well as in rat and chick embryo U87 
tumors (Strojnik et al., 2006; Strojnik et al., 2010). They stained for CD68 in the same way as 
macrophages do. Again, only minor differences in CD68 expression between animal models 
were noted. In accordance with the strong immune reaction for CD68 in all our samples we 
believe, that tumor cells adopted macrophage phenotype due to dedifferentiation.  
Vascular endothelial growth factor (VEGF) is a potent mitogen specific for vascular 
endothelial cells and may directly stimulate the growth of new blood vessels (Leung et al., 
1989). Angiogenesis is induced by tumor cell hypoxia and pro-angiogenetic factors 
(Hendriksen et al., 2009). Both brain tumor models showed only low VEGF expression. The 
slightly higher levels of vascular endothelial proliferation seen in rat tumors may be 
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explained by the likelihood of greater hypoxia associated with larger tumor size. It is well 
known that hypoxia is a potent VEGF trigger.  
Leukocyte esterase is an enzyme present in most white blood cells. Neutrophils are present 
in glioblastoma tissue and not limited to necrotic areas. Researchers reported correlation 
between tumor grade and the extent of the neutrophil infiltration (Fossati et al., 1999). Their 
role in glioma progression remains unclear. Extensive leukocyte infiltration was observed in 
the brain tumor models in our study (Strojnik et al., 2010). This might partially be explained 
by the fact that xenotransplant acts as a foreign body in both animal models, and perhaps 
that esterase acts similarly to cathepsins thus contributing to the degradation of extracellular 
matrix.  
Nestin has been detected in primary CNS tumors (Dahlstrand et al., 1992). We showed that 
nestin could be used as a biological marker for glioma malignancy (Strojnik et al., 2007). 
Contrary to the weak nestin expression of the U87 clone in cell cultures, immunostaining 
was absent in the spheroids. A switch to further dedifferentiation in the host might explain 
the moderate staining in the first generation tumors induced by inoculation of U87 cells or 
spheroids, as well as in the second and third generations of tumors induced by implantation 
of tumor tissue. The U87 cell suspension presented a weak immune reaction for musashi 
and, in contrast to nestin, its expression increased in the tumor cells as the tumor 
progressed, perhaps related to their malignant growth and dedifferentiation.  
Tissue kallikreins have recently been strongly associated with tumor progression 
(Diamandis et al., 2004). Most of the tumor cells in suspension, spheroids and in tumors of 
all three generations presented a strong immune reaction for kallikrein 6, whereas the 
expression in the vascular endothelia of the tumor and in the surrounding brain was weak 
or absent. Normal and edematous rat brain tissue showed weak expression of kallikrein. 
Strong kallikrein 6 immunostaining in the U87 cell suspension and in tumors induced by 
injection of spheroids and implantation of tumor tissue indicated the role of kallikrein in 
tumor growth.  
In conclusion, both animal models, the U-87 human glioblastoma spheroid cell line 
inoculated in rats or onto the chick embryo CAM, provide a good system for experimental 
studies of human malignant brain tumors. The panel of marker protein expression was 
followed in animal tumors. The data from rat study indicated that tumor progression was 
characterized by increased cell proliferation and tumor cell dedifferentiation, but lower 
invasiveness of the resulting tumors. Increased angiogenesis indicated high malignancy of 
the higher tumor generation. Data from the comparison of a panel of immunohistochemical 
markers between the CAM and rat models indicates that tumor protein expression in the 
CAM model is sufficiently similar to the rat model. We believe that the chick embryo CAM 
model is a good alternative to rodent brain tumor models. Anyway, both models may 
provide the basis for multigenetic and multimolecular glioma tumor cell analyses. They also 
have a potential use in testing individualized therapies. 
2.2 Immunohistochemical staining and prognostic impact of biological markers in 
glioma 
More than hundred patients with primary tumor of central nervous system (CNS), operated 
at our institution were studied. The histological slides of all cases were reviewed and 
classified according to the WHO classification of brain tumors (Kleihues & Cavenee, 2000). 
Patients’ clinical and radiological data were collected, including age, sex, date and type of 
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initial operation, clinical neurological examination, computer tomography (CT) features and 
data of adjuvant therapy. For the survival analyses the follow-up data were registered. 
Immunohistochemical staining was performed using the standard technique (Strojnik et al, 
1999; Strojnik et al., 2005). The staining for markers was scored separately for the tumor 
cells, the endothelial cells, and/or the macrophages, as described previously (Strojnik et al, 
1999; Strojnik et al., 2005; Strojnik et al., 2007; Strojnik et al., 2009). IHC staining was 
performed for various marker including cathepsins B and L, nestin, musashi, CD68, 
kallikrein 6 and Ki-67. Statistical analysis was performed using the program Statistica for 
Windows 6 (StatSoft, Inc., Tulsa, OK, USA). Overall survival probabilities were calculated 
by the Kaplan-Meier Method (Kaplan & Meier, 1958, as cited in Strojnik et al., 1999); log-
rank test was used to evaluate the association between survival and each of the selected 
markers.  
It is unique that the panel of markers was tested on the same group of patients. The fact is 
that many published biomarker studies in gliomas investigate one, two or maybe three 
potential markers in their tumor samples. In our successive investigations of numerous 
markers we were working on the same group of glioma patients, what enables us to 
compare the prognostic significance of different tumor markers.  
2.2.1 Cysteine proteinases cathepsins B and L  
Endopeptidases, including cystein proteinase cathepsin (Cat) B, are suggested to be useful 
prognostic factors in many types of cancer (Lah & Kos, 1998). McCormick first found that 
Cat B is abundantly secreted in human gliomas in vitro as a latent zymogen requiring 
activation (McCormick, 1993). Cat B expression at the protein and mRNA levels was later 
shown to correlate with the malignant progression of gliomas (Rempel et al., 1994; 
Sivaparvathi et al., 1995). The first immunohistochemical (IHC) study on Cat B in gliomas 
was performed by Mikkelsen et al. (Mikkelsen et al., 1995), which not only confirmed such 
an association, but also found high Cat B expression in endothelial cells of new vasculature 
within the tumors.  
In our study we have demonstrated that cathepsin B is expressed in glial tumor cells, 
macrophages near vessels adjacent to necrotic area, and proliferative endothelial cells of 
primary tumors of the CNS (Strojnik et al., 1999). Significantly more cases with high Cat B 
IHC score in tumor and in endothelial cells were observed in malignant compared with 
benign tumors. 
Our results confirm the previous IHC study (Sivaparvathi et al., 1995) which showed more 
frequent and intense immunostaining for Cat B in more malignant forms of brain tumors. 
Similarly, another group (Mikkelsen et al., 1995) found the highest Cat B IHC score in GBM, 
compared with anaplastic astrocytoma and normal brain. Moreover, both groups reported 
heterogeneity in the staining intensity and its regional distribution, with the proliferative 
tumor margin staining more intensely than the tumor core. Researchers (Rempel et al., 1994) 
also observed altered subcellular localization of Cat B.  They found Cat B expression to 
correlate with increased histological and radiological evidence of invasion (Rempel et al., 
1994), which is consistent with the strong association of Cat B with the clinical and 
histological paramaters, indicating advanced tumors in our study. There is, thus, in general 
agreement that brain tumor progression is associated with increased expression of Cat B in 
tumor cells (Strojnik et al., 1999). Cat B immunostaining in proliferative endothelial cells was 
first reported by Mikkelsen et al., 1995, although Cat B immunostaining was lower in 
www.intechopen.com
 
Advances in the Biology, Imaging and Therapies for Glioblastoma 
 
88
endothelial than in tumor cells, as we observed in benign tumors. However, endothelial cell-
associated Cat B immunostaining was present in about two-thirds of malignant tumors, 
compared with less than one-tenth of the benign tumors. Different models of in vivo 
angiogenesis have been proposed (Paku, 1998) and, according to them, one may speculate 
that Cat B actively participates in the intracellular lumen formation within the endothelial 
cell and/or that the secreted forms of Cat B directly degrade the ECM proteins (Buck et al., 
1992; Liotta et al., 1991). Irrespective of the mechanism, our data implicate Cat B with brain 
tumor-induced angiogenesis.  
 
 
Fig. 7. Glioblastoma multiforme. Cat B antibody shows positively stained tumor cells and 
strong positive staining in endothelial cells (x40) 
Our study (Strojnik et al., 1999) is the first clinical study on prognostic impact of Cat B in 
tumors of the central nervous system (CNS) and shows that the survival time is significantly 
longer in patients with low total immunostaining score, as compared with patients with 
strong staining. Intense Cat B staining of endothelial cells is prognostically important in 
patients with glioblastoma, indicating significantly shorter survival.  
To summarize, we have demonstrated that immunostaining of cathepsin B correlated with 
high histological score and was significantly associated with poor clinical symptoms. The 
level of expression of cathepsin B in tumor and endothelial cells is a strong prognostic 
marker for primary tumors of the CNS. Intense immunostaining of cathepsin B in 
endothelial cells may be used to predict the survival of glioblastoma patients and, in 
addition, it indicates the involvement of cathepsin B in tumor-associated angiogenesis. 
These results suggest that the therapeutic application of cystein proteinase inhibitors should 
be targeted to both tumor and endothelial cells.  
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Fig. 8. Cat B in tumor and endothelial cells, and survival in all tumors 
 
 
Fig. 9. Cat B in endothelial cells, and survival in glioblastoma multiforme 
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To complement our work we measured the expression of cathepsin L in the same 
population of human glioma patients (Strojnik et al., 2005). Cat L expression is also elevated  
in various types of human tumors (Lah & Kos, 1998) and its levels were prognostic for 
survival of patients with breast carcinoma (Thomssen et al., 1995). The only previous study 
of Cat L in brain tumor demonstrated that Cat L expression and activity correlated 
positively with increased malignancy of human glioma (Sivaparvathi et al., 1996b). We 
(Strojnik et al., 2005) have confirmed that in gliomas, cathepsin L is found predominantly in 
the malignant tumor cells. Cat B staining was expressed in both tumor and endothelial cells 
to the same extent. In contrast, Cat L was expressed significantly more in tumor cells than in 
the endothelilal cells. Although Cat L concentrations in all tumors appear to be lower than 
Cat B, we found significantly higher expression of Cat L in malignant than in benign 
gliomas. This implies a role for Cat L in malignant transformation of brain tumor cells. We 
also confirmed the correlation between immunostaining of Cat L in tumor cells and the 
histological score, i.e. the stage of glioma malignancy. Cat L and Cat B IHC staining 
correlated significantly. However, in contrast to Cat B (Strojnik et al., 1999), another study 
(Strojnik et al., 2005) did not reveal any prognostic value of Cat L, either in tumor or in 
endothelial cells.  
 
 
Fig. 10. Immunohistochemical staining of cathepsin L in glioblastoma multiforme (x40); Cat 
L antibody shows strong positive immunostaining in tumor cells but no staining in 
endothelial cells  
In conclusion, Cat L is preferentially expressed in tumor cells, increasing with glioma 
progression, but is not significantly associated with new vasculature of glioblastoma. In 
contrast to Cat B, Cat L has no prognostic impact, suggesting different roles of the two 
cathepsins in glioma progression.  
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2.2.2 Neural stem cell markers nestin and musashi proteins 
To identify other possible biological markers we studied nestin and musashi proteins, which 
are expressed by neural progenitor cells during CNS development. Nestin is an intermediate 
filament (IF) protein involved in the organization of the cytoskeleton, but it has also been 
implicated in cell signaling, organogenesis, and cell metabolism (Fuchs & Weber, 1994). Class 
VI IF nestin is expressed abundantly during early embryogenesis in neuroepithelial stem cells 
but is absent in most cells of the mature CNS (Lendahl et al., 1990). Nestin is down-regulated 
in mature cells (Steinert & Liem, 1990). It may be expressed in astrocytes of the adult CNS in 
response to cellular stress, such as neoplastic transformation (Dahlstrand et al., 1992; Tohyama 
et al., 1992). Nestin has been detected in primary CNS tumor but not in carcinoma metastases 
(Dahlstrand et al., 1992; Ikota et al., 2006).  
The musashi family is an evolutionarily conserved group of neural RNA-binding proteins 
(Okano et al., 2002, as cited in Strojnik et al., 2007). Musashi 1 is selectively expressed in 
neural progenitor cells, including neural stem cells (Kaneko et al., 2000, as cited in Strojnik et 
al., 2007). Its expression is down-regulated with the progression of neurogenesis (Toda et al., 
2001). The aim of our study (Strojnik et al., 2007) was to estimate the levels of nestin and 
musashi in tumor and endothelial cells of low- and high-grade gliomas with a view to 
correlate the levels to the histopathological score. A comparison was also made to the other 
prognostic markers, Cat B and L. 
Recently, it has been reported that the immunohistochemical detection of nestin expression 
could be used as indicator of dedifferentiation and progression in astrocytomas (Ehrmann et 
al., 2005). Nestin is a useful marker for examining the infiltration of malignant cells into 
surrounding tissue (Kitai et al., 2010). In our study tumor cells from low-grade astrocytomas 
contain low levels of nestin and most high-grade gliomas express high levels of nestin 
(Strojnik et al., 2007). 
It was proposed that nestin plays a role in tumor invasion of melanomas (Florenes et al., 
1994, as cited in Strojnik et al., 2007).  Nestin may therefore correlate with other markers of 
invasiveness, such as cysteine cathepsins B and L, which are both highly up-regulated in 
high-grade gliomas (Lah et al., 2000; Levičar et al., 2002; Sivaparvathi et al, 1995). In our 
study, a positive correlation between Cat B and nestin was established in high-grade 
gliomas, both markers correlating with the malignancy, as defined by histological scores. 
The exact location of nestin-positive cells was determined by mapping the distribution of 
nestin in highly invasive human glioma xenograft model. IHC staining of nestin in a 
xenograft model showed that nestin-positive cells are more abundant at the transition zone 
of the tumor, as reported for Cat B (Mikkelsen et al., 1995; Rempel et al., 1994). Given that 
invasion is associated with poor prognostic outcome for glioma patients, it is not surprising 
that nestin proved a very strong prognostic factor.  
It is therefore reasonable to suggest that the switch to malignancy is associated with a 
significant increase of neural progenitor markers and with high expression of the invasive 
marker Cat B. Nestin expression correlated with lysosomal Cat L, which has been shown to 
be associated with glioma cell invasiveness but was not prognostic in our population of 
patients. This may be due to other biologic functions of Cat L associated, for example, with 
the cell cycle (Levičar et al., 2003) that may be less favorable for tumor progression. By 
multivariate Cox regression analysis, only nestin remained a good prognosticator of 
following variables: patients’ age, sex, immunohistochemical scores in tumor and 
endothelial cells for nestin, cathepsin B and cathepsin L. In previous study (Strojnik et al., 
1999), only univariate analysis was performed for Cat B staining in tumor cells, which 
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(a) 
 
 
(b) 
Fig. 11. Immunohistochemical staining of nestin protein in tumor and endothelial cells in 
glioblastoma (a) and astrocytoma (b). Intense staining of nestin is seen in the cytoplasm of 
tumors cells and is more abundant in the high (a) than in the low-grade (b) tumors. The IHC 
staining of nestin in endothelial cells was the same in the high- and low-grade groups. 
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showed prognostic significance (p < 0.03) but increased to p < 0.003 when both tumor and 
endothelial cells were considered. In multivariate analysis, it is not unusual, that one 
prognosticator falls out of the significance limits when compared simultaneously with much 
stronger prognosticator – in our case, the nestin.  
 
 
Fig. 12. Survival analyses. Patients stratified according to the median IHC score for nestin 
(high score or low score) in tumor and endothelial cells combined. 
We have shown that the musashi protein is expressed, to a higher extent, in high-grade 
tumor cells than in those in the low-grade tumors. The expression of musashi was 
significantly weaker than that of nestin in tumor cells of the high-grade tumors (Strojnik et 
al., 2007). This differential expression pattern of the two neural progenitor cell markers in 
gliomas suggests that these two proteins may be stopped early (musashi) and late (nestin) in 
the BTSC “dedifferentiation” during GBM progression. Musashi is a marker of asymmetric 
cell division and is probably expressed as an early marker in stem/progenitor cell 
development. The fact that the musashi expression did not correlate with any prognostic 
factors may be related to the transformation process where the regulatory function of 
musashi is lost or changed. The difference in the prognostic impact of both stem cell 
markers is related to their different functions also. We hypothesize that these functions may 
be related to the invasiveness of possible stem/progenitor cell subpopulations. This is based 
on the observations that cathepsins, particularly Cat B – also the marker of glioblastoma cell 
invasiveness – strongly correlated with the nestin but not with the musashi expression.  
It is noteworthy that Cat B and, to a lesser extent, Cat L, as well as nestin, were present in the 
endothelial cells. The cathepsins have been suggested to play a role in angiogenesis, possibly 
also assisting endothelial cell invasion during capillary formation (Caserman & Lah, 2004), 
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particularly in GBM (Mikkelsen et al., 1995; Strojnik et al., 1999). Expression of Cat B, but not 
Cat L, in endothelial cells of high-grade tumors is significantly higher than in low-grade 
astrocytomas and can be used as a prognostic factor for GBM patients (Strojnik et al., 2005). 
 
 
(a) 
 
(b) 
Fig. 13. Immunohistochemical staining of musashi protein in tumor and endothelial cells in 
glioblastoma (a) and astrocytoma (b). Musashi immunostaining was weak in endothelial 
cells of high-grade tumors. 
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Tumor angiogenesis may be initiated by various mechanisms, for example, “bursting” of 
new capillaries from the established blood vessels and by attracting angiopoietic stem cells 
from bone marrow. All the repertoire of protein markers for these stem cells is not known. 
As the musashi and nestin may be also the markers for the cancer-associated angiopoietic 
stem cells, we have also paid the attention to the fact that nestin, but, to a much lesser extent, 
the musashi, was indeed expressed in the endothelial cells. We showed that nestin was 
expressed in endothelial cells in both low- and high-grade tumors, whereas musashi was 
expressed only to a limited extent in endothelial cells in the high-grade tumors. We have 
therefore also estimated their potential impact on the prognosis. The latter was not found 
significant. However, the further research should confirm the hypothesis derived from our 
data, that is, that angiogenesis also may result predominantly from the bone marrow stem 
cells attracted to and differentiating onto blood vessels within the tumor.     
On summary, we have confirmed that nestin is expressed in tumor cells and in endothelial 
cells of primary gliomas to a greater extent than musashi. In our clinical study on the 
prognostic impact of the neural progenitor cell markers nestin and musashi in tumors of the 
CNS, the high level of nestin, but not musashi, in tumor cells indicates significantly shorter 
survival of glioma patients. Intense immunostaining of nestin in tumor cells may be used to 
predict the risk of death in patients with malignant primary tumors of the CNS. Moreover, 
by multivariate analysis, nestin presents as the best prognosticator of all the variables.  Our 
data links the invasive glioma cells to CNS precursor cells, indicating that the most 
malignant cells in the gliomas may well be closely related to the glioma stem cells.  
2.2.3 Expression of kallikrein 6 and CD68 in human gliomas 
Subsequent study (Strojnik et al., 2009) was designed to evaluate the expression of kallikrein 
6 and CD68 in human glioma, and investigate their prognostic significance for survival of 
brain cancer patients in comparison to previous established prognostic markers.  
Kallikreins are expressed by secretory epithelial cells of many organs and have been 
implicated in a range of normal physiological functions. Some of the kallikreins are known 
for their clinical application as cancer biomarkers: for example kallikrein 3, which is known 
as prostate-specific antigen (PSA), is one of the best available biomarkers for monitoring 
tumor burden in sera of prostate cancer patients and has also been evaluated as a marker for 
prostate cancer diagnosis and prognosis (Loeb & Catalona, 2007). In vitro data and animal 
experiments have indicated the role of kallikreins in several steps of tumor progression, 
such as tumor growth, invasion and metastasis, as well as increased angiogenesis (Borgoño 
et al., 2004; Borgoño & Diamandis, 2004; Lundwall et al., 2006). 
Kallikreins are also widely distributed in various areas of the human brain (Raidoo et al., 
1996). It has been suggested that the functional role of kallikreins is to assist in the normal 
turnover of brain proteins and the processing of peptide hormones, neurotransmitters and 
nerve growth factors that are essential for normal neuronal function and synaptic 
transmission (Borgoño et al., 2004; Borgoño & Diamandis, 2004). Kallikrein 6 is among the 
members of the kallikrein family with high levels of expression in the brain and related 
fluids (Yousef at al., 2003); however, knowledge of the expression of kallikreins by brain 
tumors is limited. The objective of our study (Strojnik et al., 2009) was to evaluate the 
possible prognostic impact of serine protease kallikrein 6 in gliomas. Kallikrein 
genes/proteins are aberrantly expressed in many cancer types and they may exert diverse 
and often contrasting effects on the tumor and its microenvironment. Therefore, high 
kallikrein expression has been associated with either poor or favorable patient prognosis. 
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Some members of the kallikrein family are listed among the group of tumor-protecting 
proteases (Lopez-Otin & Matrisian, 2007), but even a single kallikrein may have a dual role 
in tumor progression. We (Strojnik et al., 2009) demonstrated higher IHC expression of 
kallikrein 6 in tumor cells of benign human gliomas comparing to malignant tumors. 
 
 
(a) 
 
(b) 
Fig. 14. Immunohistochemical staining of astrocytoma with kallikrein 6 antibody revealed 
strong immunostaining in tumor cells (a) while in glioblastoma staining was weaker (b) 
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Our data support a potential role of kallikrein 6 in suppression of glioma progression, 
however, a prognostic value of kallikrein 6 was not revealed by our study. The possibility of 
a dual role (pro- and antitumor) of kallikrein 6 in tumor growth cannot be overlooked. 
Clinical studies with larger patient populations are needed to allow further evaluation of 
kallikrein 6 function in glioma progression.  
CD68 is a transmembrane glycoprotein, expressed by monocyte/macrophage lineages and 
serves as a marker for microglia (Hulette et al., 1992). Microglial cells function as resident 
immune cells and phagocytes in the CNS. In response to pathology, resident microglia 
follows a stereotyped pattern of first becoming activated and then phagocytic (Trapp & 
Herrup, 2004). On one hand, microglia may represent components of the antitumor immune 
response in the CNS, which is inactivated by local secretion of immunosuppressive factors 
by glioma cells. On the other hand, taking into account that microglia are capable of 
secreting a variety of immunomodulatory cytokines, they may be attracted by the gliomas to 
assist in tumor growth (Badie & Schartner, 2001; Graeber et al., 2002). In human glioma, 
intratumoral microglia density is higher than in peritumoral and normal brain, and 
microglia increase in number according to grade of malignancy (Roggendorf et al., 1996; 
Morris & Esiri, 1991). It has been evidenced that microglia accumulation in diffuse glial 
tumors does not merely represent a nonspecific reaction to tissue injury but reflects 
participation of these cells in supporting and promoting the invasive phenotype of 
astrocytoma cells (Bettinger et al., 2002).  
Notably, tumor cells can occasionally be reactive to some macrophage markers (Leenstra et 
al., 1995). They investigated six specimens of cultured astrocytoma cells and reported that 
nine macrophage markers, including CD68, were clearly reactive in neoplastic astrocytes, 
whereas astrocytes in normal brain specimens were not reactive (Leenstra et al., 1995). This 
study suggested that the demonstration of macrophages within astrocytoma by using 
macrophage-specific antibodies alone must be cautiously considered. In accordance with 
quoted studies, we also found strong CD68 expression in tumor cells of U87 human 
glioblastoma cell suspension, in U87 spheroids (both prepared from the U87 human 
glioblastoma cell line without microglia), as well as in induced rat tumors (Strojnik et al., 
2006). In our CD68 study (Strojnik et al., 2009) we considered the possibility that human 
malignant astrocytes may adopt a macrophage phenotype and aimed to evaluate the 
possible prognostic value of CD68 expression for the survival of brain tumor patients. Both 
microglia and tumor cells expressed CD68. High CD68 staining score was significantly more 
frequent in the malignant than in the benign tumors. 
We evaluated the antigen expression of CD68 in glioma tissue by avoiding any region 
with necrosis and excluding foamy cells, possibly indicating the presence of 
macrophage. However, malignant astrocytoma cells were also highly CD68 positive, in 
accordance with another report (Leenstra et al., 1995). These authors further 
emphasized that there may be biological properties shared by macrophages and 
astrocytoma cells, such as phagocytosis and production of the same growth and 
angiogenic factors. These common properties may be explained: (a) by genetic 
alterations during malignant transformation of astrocytes; (b) by fusion of astrocytes 
with macrophages; or (c) by another, as yet unknown, mechanism of gene transfer 
during glioma progression (Leenstra et al., 1995). These may lead to significantly higher 
CD68 immunostaining of the malignant glioma.  
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Fig. 15. Prognostic significance of immunolabeling for CD68 (low and high IHC score) for 
the survival of all patients with primary brain tumors 
Survival analysis revealed that CD68 tumor staining has a prognostic value for glioma 
patients, comparable to that of cathepsin B. Within the malignant group, intense CD68 
staining was marginally significant prognosticator for shorter survival. Notably, there was a 
significant prognostic value of CD68 tumor staining in the group of patients with anaplastic 
astrocytoma, which may be important for the management of patients with longer survival 
than these with glioblastoma. Further studies are necessary to investigate the possible 
mechanisms and consequence of macrophage phenotype expression of malignant 
astrocytomas, as well as possible role of microglia for tumor progression and patient 
prognosis. 
To resume, kallikrein 6 was down-regulated in malignant glioma, but this differential 
expression did not have an impact on patient prognosis. In contrast, immunostaining of 
glioma tissue for CD68, as well as for Cat B and nestin, may be used as prognostic marker 
for survival of glioma patients. This finding suggests that besides the known role of Cat B in 
invasion and angiogenesis, nestin and CD68 may be also associated with glioma progression 
(Strojnik et al., 2007; Strojnik et al., 2009). 
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(a) 
 
 
(b) 
 
Fig. 16. Treatment of astrocytoma (x40) with CD68 antibody resulted in a few positively 
stained tumor cells (a); immunohistchemical staining of CD68 in glioblastoma multiforme 
(x40) revealed strong reaction in almost all tumor cells (b) 
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3. Conclusion 
In recent years there have been many publications in the area of immunohistochemistry in 
brain tumor pathology (Takei et al., 2007; Dunbar & Yachnis, 2010; Ikota et al, 2006). 
Extensive molecular studies have identified diagnostic and prognostic markers in gliomas 
(Labussiere et al., 2010). They can assist in diagnosis, provide prognostic information and 
potentially predict response to therapy (Rivera & Pelloski, 2010). As we mentioned above, 
we combined the clinical work by different experimental glioma models. Animal tumor 
sections were examined for tumor markers by routine haematoxylin and eosin staining and 
immunohistochemical analyses. Established animal models provide a basis for further 
experimental studies of genetic and protein expression fingerprints during human glioma 
tumorigenesis. Furthermore, in a present paper we reviewed clinical and experimental work 
in glioma patients operated at our department of neurosurgery. Immunohistochemical 
studies supplement conventional H&E histology. Immunohistochemically we evaluated the 
expression of possible biological markers in human gliomas, including proteolytic enzymes 
(cathepsins B and L), neural stem cell markers (nestin, musashi), marker for microglia 
(CD68) and others (e.g. kallikrein 6). Differently from other reports, we performed 
immunohistochemical staining for the panel of markers on the same group of patients. 
Increased expression of lysosomal cystein proteinases such as cathepsins B and L plays a 
functional role in tumor cell migration and metastasis (Lah et al., 2000). We found that Cat B 
expression was highly elevated in GBM compared to lower grade malignant tumors and 
benign tumors. Cat B was also highly expressed in the endothelial cells of about two third of 
GBM. The latter finding indicates that Cat B may be associated with the invasion of not only 
tumor but also endothelial cells in the process of angiogenesis. At the end of the nineties we 
first published the clinical study on prognostic impact of Cat B in tumors of CNS, revealing 
that survival time in all patients with weak total immunostaining score is significantly 
longer compared to survival of patients with strong staining. Intense Cat B staining of 
endothelial cells is also prognostic important in patients with glioblastoma indicating 
significantly shorter survival. Cat L is preferentially expressed in tumor cells, increasing 
with glioma progression, but is not significantly associated with new vasculature of 
glioblastoma. Nestin is expressed in tumor cells of primary gliomas to a greater extent than 
musashi. Nestin-positive tumor cells are localized more abundantly in the transition zone of 
the tumor.  Nestin is expressed in the endothelial cells in both low- and high-grade tumors, 
whereas musashi is expressed only to a limited extent in endothelial cells in the high-grade 
tumors. The further research should confirm the hypothesis derived from our data, that is, 
that angiogenesis also may result predominantly from the bone marrow stem cells attracted 
to and differentiating onto blood vessels within the tumor. Nestin is shown to be a strong 
prognostic marker for glioma malignancy. Our study revealed that both microglia and 
tumor cells expressed CD68. Malignant astrocytoma cells were highly CD68 positive in 
accordance to previous report (Leenstra et al., 1995). We found that some authors 
recommended to identify macrophages on intraoperative consulatiton to distinguish a 
neoplastic process from a demyelinating (or other destructive noneoplastic) disorder using 
IHC staining for CD68 (Dunbar & Yachnis, 2010). We point out that the demonstration of 
macrophages within the astrocytomas by using macrophage-specific antibodies alone must 
be cautiously considered. We further conclude that specific immunostaining of CD68 in 
tumor cells can be used to predict the risk of overall death in patients with glioma. 
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Noteworthy, we found prognostic value of CD68 immunostaining in tumor cells in 
anaplastic astrocytoma, which may be important for the management of patients with 
longer survival than these with GBM. 
Taken together our data show that brain tumor progression is associated with increased 
expression of Cat B, Cat L, nestin and CD68 in tumor cells. We mentioned the role of Cat B 
and nestin in angiogenesis. IHC studies of biological markers provide important 
information about gliomagenesis. Biological marker can also assist in diagnosis. 
Immunohistochemistry has provided us with the ability to differentiate between tumors that 
are histologically indistinguishable. With this tool, we can now attribute the unpredictable 
behavior of what was once recognized as one tumor type to the more predictable behaviors 
of multiple tumors that are distinguishable based on their protein expression. The most 
challenged is to use findings for target therapy. Screening for the invasiveness of the 
individual brain tumor might help the neurosurgeon to define his strategy for further 
postoperative treatment of a given brain tumor.  
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